2023 World Conference on Lung Cancer (Posters)-P1.08. Impact of KRASG12D Subtype and Concurrent Pathogenic Mutations on Advanced Non-small Cell Lung Cancer Outcomes

P1.08. Impact of KRASG12D Subtype and Concurrent Pathogenic Mutations on Advanced Non-small Cell Lung Cancer Outcomes - PDF(Abstract)

Back to course

Pdf Summary

This document provides a summary of a presentation at the WCLC 2023 conference titled "Impact of KRASG12D Subtype and Concurrent Pathogenic Mutations on Advanced Non-small Cell Lung Cancer Outcomes." The study aimed to investigate the impact of different KRAS mutation subtypes and concurrent genetic alterations on the clinical outcomes of non-small cell lung cancer (NSCLC) patients in Latin America.<br /><br />The researchers conducted a retrospective observational study at the National Cancer Institute of Mexico, analyzing samples from 345 NSCLC patients using next-generation sequencing. Of these patients, 50 had KRAS mutations, with G12D and G12C being the most prevalent subtypes. Concurrent pathogenic mutations were also identified in genes such as TP53, STK11, EGFR, and GNAS.<br /><br />The study found that KRASG12D mutations were significantly associated with female sex and never smoking. Compared to KRASnon-G12D cases, KRASG12D NSCLCs were enriched in mutations affecting EGFR and CDKN2A genes. On multivariable analysis, KRASG12D mutations were found to be significantly associated with better progression-free survival (PFS) and overall survival (OS).<br /><br />The researchers concluded that among NSCLC patients with KRAS mutations, the G12D subtype was associated with significantly better PFS and OS. They also found that differences in prognosis among Latin American populations may be attributed to factors such as lower smoking exposure and divergent patterns of concurrent mutations, particularly in women.<br /><br />In summary, this study highlights the importance of considering different KRAS mutation subtypes and concurrent genetic alterations in predicting outcomes for advanced NSCLC patients. Understanding these factors may contribute to personalized treatment strategies for Latin American populations.

Asset Subtitle

Norma Hernandez-Pedro

Meta Tag

Speaker Norma Hernandez-Pedro

Topic Tumor Biology: Translational Biology - Drug Resistance

Keywords

KRASG12D

subtype

concurrent pathogenic mutations

advanced non-small cell lung cancer

Latin America

retrospective observational study

EGFR mutations

CDKN2A mutations

progression-free survival

overall survival